Epigenetic Therapy of Cancer
Preclinical Models and Treatment Approaches
Buch in deiner Nähe kaufen
Beschreibung
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
Devotes detailed attention to the translation of basic research and drug development to clinical applications in the treatment of solid tumors as well as hematologic malignancies and hemoglobinopathy Presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production Discusses DNA methylation abnormalities in depth
Autor*in
Michael Lübbert
Themen in »Epigenetic Therapy of Cancer«
Carcinoma Chromatin DNA Methylation Histone Organisation Myelodysplasia gene therapy
Stimmen zu »Epigenetic Therapy of Cancer«
From the reviews:
“This new book covers the timely topic of epigenetic therapy. … The combination of articles describing the basic science framework of epigenetics and the detailed summaries of clinical trials with epigenetic drugs is attractive for a wide readership, ranging from medical students to scientists who are interested in translational studies to clinicians who work for the direct benefit of cancer patients. … This high-quality book is an excellent overview of the current success and future promise of epigenetic therapy.” (Gerd Pfeifer, Doody’s Book Reviews, May, 2014)()